Gil M. Labrucherie Sells 3,767 Shares of Nektar Therapeutics (NKTR) Stock

Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,767 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $118,170.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Gil M. Labrucherie also recently made the following trade(s):

  • On Tuesday, February 19th, Gil M. Labrucherie sold 3,592 shares of Nektar Therapeutics stock. The shares were sold at an average price of $42.39, for a total transaction of $152,264.88.

Shares of NKTR opened at $32.02 on Monday. The stock has a market cap of $5.58 billion, a PE ratio of 8.47 and a beta of 2.96. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $92.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. The business had revenue of $28.22 million for the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter in the prior year, the company earned ($0.60) earnings per share. As a group, analysts predict that Nektar Therapeutics will post -3.14 EPS for the current year.

A number of research analysts have commented on the stock. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. BidaskClub cut shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 27th. BMO Capital Markets assumed coverage on shares of Nektar Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $75.00 target price on the stock. ValuEngine cut shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 22nd. Finally, Svb Leerink assumed coverage on shares of Nektar Therapeutics in a research report on Friday, March 15th. They issued a “mkt perform” rating and a $38.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $69.73.

Several institutional investors and hedge funds have recently modified their holdings of NKTR. Meeder Asset Management Inc. lifted its position in shares of Nektar Therapeutics by 150.2% during the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 479 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in shares of Nektar Therapeutics during the first quarter worth about $27,000. CSat Investment Advisory L.P. lifted its position in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC acquired a new stake in shares of Nektar Therapeutics during the fourth quarter worth about $39,000. Finally, Sandy Spring Bank acquired a new stake in shares of Nektar Therapeutics during the fourth quarter worth about $59,000. 94.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://macondaily.com/2019/05/20/gil-m-labrucherie-sells-3767-shares-of-nektar-therapeutics-nktr-stock.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Further Reading: Straddles

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.